Table 3.
Selected ongoing clinical trials of drugs targeting the PI3K/AKT/mTOR pathway in prostate cancer, adapted from clinicaltrials.gov
| Target | Agent | Phase | Summary | Identifier |
|---|---|---|---|---|
| mTOR VEGF |
Everolimus Bevacizumab |
Ib/II | Dose-finding/efficacy study; Docetaxel + RAD001 (everolimus) and bevacizumab in metastatic CRPC |
NCT00574769 |
| mTOR VEGF |
Temsirolimus Bevacizumab |
I/II | Dose-finding/efficacy study; Temsirolimus + bevacizumab in metastatic CRPC |
NCT01083368 |
| mTOR | Everolimus | I/II | Dose-finding/efficacy study; Docetaxel + RAD001 (everolimus) in metastatic CRPC |
NCT00459186 |
| mTOR IGF-1R |
Temsirolimus Cixutumumab |
I/II | Dose-finding/efficacy study; Temsirolimus + cixutumumab in metastatic CRPC |
NCT01026623 |
| mTOR AKT Notch |
Ridaforolimus MK2206 MK0752 |
I | Dose-finding study; Ridaforolimus + MK2206 or MK0752 in solid tumors including metastatic CRPC |
NCT01295632 |
| PI3K mTOR |
BEZ235 | I/II | Dose-finding/efficacy study; Abiraterone + BEZ235 in metastatic CRPC |
NCT01717898 |
| PI3K mTOR |
BEZ235 BKM120 |
Ib | Dose-finding study; Abiraterone + BEZ235 or BKM120 in CRPC |
NCT01634061 |
| AKT | MK2206 | II | Randomized efficacy study; Bicalutamide ± MK2206 in PSA-recurrent/non-metastatic prostate cancer |
NCT01251861 |
| PI3K | BKM120 | II | Single-arm efficacy study; BKM120 in metastatic CRPC |
NCT01385293 |
| PI3K | BKM120 | Ib | Single-arm efficacy study; Abiraterone + BKM120 in metastatic CRPC |
NCT01741753 |
| PI3K | PX-866 | II | Single-arm efficacy study; PX-866 in advanced CRPC |
NCT01331083 |
mTOR mammalian target of rapamycin, VEGF vascular endothelial growth factor, CRPC castration-resistant prostate cancer, IGF-1R insulin-like growth factor-1 receptor, PI3K phosphatidylinositol 3-kinase